Alexander Alonso – General Manager, BD Benelux
Alexander Alonso, GM of medtech giant BD’s Benelux affiliate explains the impact of the COVID-19 pandemic on its operations, the company’s 2025 strategy, and some of the most significant recent…
Address: Avenue Ariane 16 1200 Brussels Belgium
Tel: +32 (0)2 773 33 11
Web: http://www.boehringer-ingelheim.be/
The Boehringer Ingelheim group
Our group, established in Ingelheim (Germany), has 137 subsidiaries across 47 countries and approximately 41,500 employees, of which nearly 5,000 are active in research and development.
Since its foundation in 1885, the group is still wholly owned by the founding family and focused on researching, developing and producing and marketing of new products with high added value for medical use, also in veterinary medicine.
In Belgium and Luxembourg Boehringer Ingelheim employs over 250 staff working in the sales and distribution of pharmaceutical products for humans and animals and in clinical research.
With research as our main growth engine, developing our laboratories breakthrough medicines for use in diverse areas such as pneumology, cardiology, rheumatology, neurology, virology and oncology. Boehringer Ingelheim also develops products for self-medication and phyto-pharmaceuticals, and a series products for veterinary use. Our activities extend also to the chemical and biopharmaceutical manufacturing. Our main activity in Belgium includes the sale and distribution of pharmaceutical products for humans and animals, as well as clinical research.
Alexander Alonso, GM of medtech giant BD’s Benelux affiliate explains the impact of the COVID-19 pandemic on its operations, the company’s 2025 strategy, and some of the most significant recent…
Speaking exclusively to PharmaBoardroom, Pedro Facon outlines the scope and aims of the new medicines roadmap that NIHDI has recently presented to the Belgian Ministry of Health following extensive stakeholder…
An Van Gerven took the reins of Pfizer’s BeLux affiliate just 9 months ago after a diverse range of roles at the company over the course of 12 years. She…
PDC*line Pharma’s Eric Halioula explains why he decided to establish a biotech in Belgium, outlines the progress that his immuno-oncology focused firm has made in clinical trials since our last…
Once primarily associated with dispensing medications alone, many pharmacies have now evolved into dynamic healthcare hubs, offering a diverse range of services that extend far beyond traditional prescription filling. Similarly,…
The concepts of patient-centricity and patient-centred healthcare systems have been much discussed in recent years but, in the opinion of Stefan Gijssels, there is still a long road to travel…
Pierre Boyer, GM at Servier BeLux for the past six years, outlines the unique characteristics and challenges of the Belgian market and shares the company’s 2030 strategy, its unique approach…
Gedeon Richter Benelux’s Isabelle de Walsche gives an update on the affiliate’s progress towards becoming a reference player in women’s health, looks back on some of her achievements over 11…
Luc Van Gorp is president of the Christian Mutuality, Belgium’s largest health insurance fund. In a wide-ranging recent conversation with PharmaBoardroom, Van Gorp expanded on some of the key themes…
Xavier De Cuyper of the Federal Agency for Medicines & Health Products (FAMHP), Belgium’s drug regulator, explains the FAMHP’s pandemic response and lessons learned, how the Agency is keeping on…
As part of the EU’s Pharmaceutical Strategy for Europe, the European Commission has come out with a set of proposals to revise EU pharmaceutical legislation. The reforms, which aim to…
Gábor Sztaniszláv talks through the global relevance of Belux to Amgen’s operations, some of the challenging market access conditions at play – especially for orphan drugs -, and how the…
See our Cookie Privacy Policy Here
